Cancer Genetics and StemoniX Announce Merger Closing
March 31, 2021 06:30 ET
|
Cancer Genetics, Inc.
Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc....
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
March 25, 2021 09:15 ET
|
Cancer Genetics, Inc.
Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline...
Cancer Genetics to Present at the Annual 33rd ROTH Conference
March 12, 2021 09:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference
March 04, 2021 16:15 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
February 16, 2021 16:45 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
February 10, 2021 23:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market
February 01, 2021 17:16 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
January 28, 2021 16:02 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
January 07, 2021 16:05 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
Cancer Genetics Reports Third Quarter 2020 Financial Results
November 12, 2020 16:25 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...